Amylyx Pharmaceuticals (AMLX) Receivables: 2022-2025
Historic Receivables for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Sep 2025 value amounting to $232,000.
- Amylyx Pharmaceuticals' Receivables fell 87.33% to $232,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 97.94%. This contributed to the annual value of $547,000 for FY2024, which is 98.65% down from last year.
- Per Amylyx Pharmaceuticals' latest filing, its Receivables stood at $232,000 for Q3 2025, which was up 14.29% from $203,000 recorded in Q2 2025.
- Amylyx Pharmaceuticals' Receivables' 5-year high stood at $40.5 million during Q4 2023, with a 5-year trough of $137,000 in Q3 2022.
- Moreover, its 3-year median value for Receivables was $4.2 million (2024), whereas its average is $13.7 million.
- As far as peak fluctuations go, Amylyx Pharmaceuticals' Receivables soared by 21,398.54% in 2023, and later crashed by 98.65% in 2024.
- Amylyx Pharmaceuticals' Receivables (Quarterly) stood at $15.8 million in 2022, then soared by 156.55% to $40.5 million in 2023, then slumped by 98.65% to $547,000 in 2024, then slumped by 87.33% to $232,000 in 2025.
- Its Receivables stands at $232,000 for Q3 2025, versus $203,000 for Q2 2025 and $400,000 for Q1 2025.